Metformin Hydrochloride and Empagliflozin Tablets in the Treatment of Type 2 Diabetes
NCT07003191 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 2600
Last updated 2025-06-04
Summary
The main objective of this study is to evaluate the efficacy and safety of Metformin Hydrochloride and Empagliflozin Tablets in the treatment of type 2 diabetes in real-world clinical settings. A total of 2,600 type 2 diabetes patients were included in the study. The study observed the clinical glycemic control rate and adverse events over a period of at least 6 months from the prescription date to the end of continuous clinical follow-up.
Conditions
Interventions
- DRUG
-
Metformin Hydrochloride and Empagliflozin tables (Fixed-Dose Combination)
First-time treatment with Metformin Hydrochloride and Empagliflozin Tablets (metformin 500mg and empagliflozin 5mg per table) for at least 6 months
Sponsors & Collaborators
-
First Affiliated Hospital, Sun Yat-Sen University
collaborator OTHER -
Liaoning Health Industry Group Fushun Mining General Hospital
collaborator UNKNOWN -
Liaoning Health Industry Group Benxi Steel General Hospital
collaborator UNKNOWN -
Changsha Fourth Hospital
collaborator OTHER_GOV -
Second Hospital of Shanxi Medical University
collaborator OTHER -
The First People's Hospital of Kunshan
collaborator OTHER -
Suzhou Ninth People's Hospital
collaborator UNKNOWN -
the First Affiliated Hospital of Anhui University of Science and Technology
collaborator UNKNOWN -
Mingguang People's Hospital
collaborator UNKNOWN -
the People's Hospital Longhua Shenzhen
collaborator UNKNOWN -
Affiliated Hospital of North Sichuan Medical College
collaborator OTHER -
Yiyang County People's Hospital
collaborator UNKNOWN -
THE SECOND PEOPLE'S HOSPITAL, WUHU
collaborator UNKNOWN -
The First People's Hospital of Zhangjiagang
collaborator UNKNOWN -
Yixing People's Hospital
collaborator OTHER -
Shijiazhuang People's Hospital
collaborator OTHER -
Guiyang First People's Hospital
collaborator UNKNOWN -
Lanzhou University Second Hospital
collaborator OTHER -
Tiefa Coal Industry Group General Hospital
collaborator UNKNOWN -
Southern Medical University Shenzhen Hospital
collaborator UNKNOWN -
The Second Hospital of Shijiazhuang
collaborator UNKNOWN -
Ningbo University Affiliated People's Hospital
collaborator UNKNOWN -
Dongyang People's Hospital
collaborator OTHER -
Xiangyang Central Hospital
collaborator OTHER -
Li Hui Li Hospital
collaborator UNKNOWN -
Nanning Second People's Hospital
collaborator OTHER -
Hunan Provincial People's Hospital Ma Wang Dui Branch
collaborator UNKNOWN -
The Second Affiliated Hospital of Bengbu Medical College
collaborator UNKNOWN -
Ruyang County People's Hospital
collaborator UNKNOWN -
Kaifeng People's Hospital
collaborator UNKNOWN -
Dingzhou People's Hospital
collaborator UNKNOWN -
The Second People's Hospital of Changshu
collaborator UNKNOWN -
The Second Affiliated Hospital of Henan University of Science and Technology
collaborator UNKNOWN -
Dengzhou People's Hospital
collaborator UNKNOWN -
Taizhou First People's Hospital
collaborator OTHER -
Red Cross Hospital, Hangzhou, China
collaborator OTHER -
The First People's Hospital of Lin'an District
collaborator UNKNOWN -
China Resources Wugang General Hospital
collaborator UNKNOWN -
Yiwu Central Hospital
collaborator OTHER -
The First People's Hospital of Jiashan County
collaborator UNKNOWN -
The First People's Hospital of Tongxiang City
collaborator UNKNOWN -
Shaoxing Central Hospital
collaborator OTHER -
The First People's Hospital of Jiande City
collaborator UNKNOWN -
Beilun District People's Hospital
collaborator UNKNOWN -
Huantai County People's Hospital
collaborator UNKNOWN -
Fifth Affiliated Hospital of Guangzhou Medical University
collaborator OTHER -
Sixth Hospital of Wuhan, Affiliated Hospital of Jianghan University
collaborator OTHER -
The Affiliated Hospital of Shaanxi University of Chinese Medicine
collaborator UNKNOWN -
Zhangjiagang Traditional Chinese Medicine Hospital
collaborator UNKNOWN -
Sun Yat-sen University
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-08-02
- Primary Completion
- 2025-12-31
- Completion
- 2025-12-31
Countries
- China
Study Locations
More Related Trials
-
Efficacy and Safety of Repaglinide and Metformin Combination Therapy in Type 2 Diabetes Failing on Oral Anti-diabetic Drugs
NCT00491725 ·Status: COMPLETED ·Phase: PHASE4
-
An Observational Study on the Safety and Efficacy of Henagliflozin in Chinese Patients With Type 2 Diabetes
NCT06959030 ·Status: RECRUITING
-
Evaluation of Fixed Dose Combination of Glimepiride and Metformin in Chinese Type 2 Diabetes Patients Inadequately Controlled With Metformin
NCT01457911 ·Status: COMPLETED ·Phase: PHASE3
-
Metformin Plus Insulin on Non-obese Autoimmune Diabetes
NCT03513874 ·Status: UNKNOWN ·Phase: PHASE4
-
Comparison of Metformin and Repaglinide Monotherapy in the Treatment of New Onset Type 2 Diabetes Mellitus in China
NCT02040246 ·Status: COMPLETED ·Phase: PHASE4
-
Impact of Benfluorex Versus Metformin on Glucose Control and Insulin Secretion in Chinese Type 2 Diabetic Patients
NCT00544518 ·Status: UNKNOWN ·Phase: PHASE2
-
Effects of Sequential Treatment Based on Lina/MET After Short-term Intensive Insulin in Newly Diagnosed Type 2 Diabetes
NCT03194945 ·Status: COMPLETED ·Phase: PHASE4
-
This Study is to Compare and Evaluate the Safety and Pharmacokinetic Characteristics (PK) After Administration of DW6014 and Each Component(Empagliflozin and Metformin) in Healthy Adult Volunteers in Fast Condition.
NCT05823870 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Metabolic and Haemodynamic Effects of Metformin and Glimepiride in Patients With Type 2 Diabetes Mellitus
NCT01509001 ·Status: COMPLETED ·Phase: PHASE4
-
To Compare the Similarity of a Combination Dapagliflozin/Metformin Tablet With the Two Drugs Administered Separately
NCT01535677 ·Status: COMPLETED ·Phase: PHASE1
-
Comparison of the Effects of Repaglinide and Metformin on Glucose Excursions
NCT00832481 ·Status: UNKNOWN ·Phase: NA
-
Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes
NCT01719003 ·Status: COMPLETED ·Phase: PHASE3
-
A Study Comparing the Amount of Metformin and After Taking a Combination Tablet vs. Separate Tablets
NCT01055691 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy and Safety Comparison of Cofrogliptin Add-on Versus Metformin Dose-escalation in Type 2 Diabetes Patients Inadequately Controlled With SGLT-2 Inhibitors Plus Low-Dose Metformin:A Multicenter, Open-Label Trial
NCT06863532 ·Status: RECRUITING ·Phase: NA
-
Efficacy/Safety Study of Glimepiride to Type 2 Diabetes Patients Based on Metformin And Basal Insulin Treatment
NCT02026310 ·Status: COMPLETED ·Phase: NA
-
Pharmacokinetics of Fixed Dose Combination (FDC) Tablets of Linagliptin /Metformin
NCT01540487 ·Status: COMPLETED ·Phase: PHASE1
-
Comparison of the Blood Sugar Lowering Effect Between Repaglinide Plus Metformin and Repaglinide Alone in Type 2 Diabetics Not Previously Treated With Oral Sugar-lowering Drugs
NCT00819741 ·Status: COMPLETED ·Phase: PHASE4
-
The Efficacy and Safety of DWP16001 in Combination With Metformin in Patients With Type 2 Diabetes.
NCT04634500 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Repaglinide and Metformin Combined in Type 2 Diabetes
NCT00568984 ·Status: COMPLETED ·Phase: PHASE4
-
Beta Cell Function and Related Pharmacodynamics of HMS5552 in T2DM Patients
NCT02386982 ·Status: COMPLETED ·Phase: PHASE1
-
Metformin Hydrochloride Sustained-release Tablets (Ⅲ) in Patients With Type 2 Diabetes Mellitus Complicated With Coronary Heart Disease
NCT06932874 ·Status: RECRUITING ·Phase: PHASE4
-
Metformin's Effect on Glucagon-induced Glucose Production and Protein Metabolism.
NCT01956929 ·Status: COMPLETED ·Phase: PHASE1
-
A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773) (Once Daily Versus Twice Daily) in Patients With Type 2 Diabetes Mellitus and Preexisting Metformin Therapy
NCT01649297 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Learn More About Outcomes Reported by Patients Suffering From Type 2 Diabetes Using a Digital Data Collection Tool
NCT04383041 ·Status: COMPLETED
-
A Study of GSK256073 in Subjects With Type 2 Diabetes Mellitus Who Are Being Treated With Metformin
NCT01376323 ·Status: COMPLETED ·Phase: PHASE2